[Corrections] Correction to Lancet Oncol 2023; 24: 1399–410

March, 03, 2024 | Select Oncology Journal Articles

Llovet JM, Kudo M, Merle P, et al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol 2023; 24: 1399–410—The appendix of this Article has been corrected as of March 25, 2024.

For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –




Sign up for our emails

Trusted insights straight to your inbox and get the latest updates from OncWeekly

Privacy Policy